| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 422.82% | £365,972.36 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 377.83% | £334,481.54 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 268.21% | £257,744.66 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 53.33% | £107,333.55 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 45.01% | £101,508.32 |
| Lord Mance |
|
Stryker / NYQ:SYK | 30.77% | £91,537.09 |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | 13.55% | £79,487.56 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | 11.32% | £77,925.01 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -2.15% | £68,492.61 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -39.53% | £42,332.42 |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -53.47% | £32,567.98 | |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |